Advertisement

Topics

Arch Oncology raises $50m Series B financing

02:47 EDT 26 Mar 2019 | Pharmaceutical Business Review

The Company plans to use the proceeds from this financing to advance its anti-CD47 antibody AO-176’s ongoing Phase 1 clinical trial in select solid tumors, as well as

The post Arch Oncology raises $50m Series B financing appeared first on Pharmaceutical Business review.

Original Article: Arch Oncology raises $50m Series B financing

NEXT ARTICLE

More From BioPortfolio on "Arch Oncology raises $50m Series B financing"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...